Navigation Links
Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
Date:7/5/2009

ising lantibiotic candidates in pre-clinical testing for the treatment of Gram-positive infections including MRSA and novel broad spectrum bacteriocins for the treatment of both Gram-positive and Gram-negative infections.

Following the completion of the investment, Novacta will appoint Dr. Richard Garraway and Dr. Bob Milsted, both partners of CPHA, to its Board of Directors. In a further Board change, the Chairman Dr. Andrew Sandham will retire from the Board on completion and will be replaced by Dr. Andy Richards. The new directors bring significant drug development, financial and corporate development experience to Novacta.

Commenting on the investment, John Mayo, Managing Partner of CP2 said: "The urgent need for new antibiotics is well known, Novacta represents a real opportunity to meet this significant unmet medical need in C. difficile infection, MRSA and related Gram-positive infections and Gram-negative infections, such as E. coli and Salmonella. Our investment in Novacta fits our model of taking a majority position in high quality companies with well differentiated technologies and bringing both funding and additional commercial, regulatory, drug development and manufacturing experience to increase both the probability of success and the value of the products. We are looking forward to working with the dynamic management team at Novacta under Tony Sedgwick, producing important new antibiotics and a great return for existing Novacta shareholders and Celtic Pharma investors alike."

Stephen Parker, a Partner in CP2 added: "This is the second in a series of major investments in high-quality UK biotech companies. We were delighted to see the announcement from the UK Government this week of the creation of the Innovation Investment Fund-of-funds to invest in technology-based businesses and we look forward to helping the Government fulfil its ambitions in the UK life science sector as we continue
'/>"/>

SOURCE Celtic Pharma Holdings Advisors LLP
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
2. iCardiac Selected by Top 10 Pharmaceutical Company
3. WuXi PharmaTech Receives Award from BASF
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
6. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
7. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
8. OncoGenex Pharmaceuticals Added to Russell Indexes
9. Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland
10. Pharmaxis Closes Share Purchase Plan
11. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Texas (PRWEB) November 21, 2014 ... is a professional and in-depth research report on ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:11/21/2014)... , Nov. 20, 2014 /CNW/ - Aequus Pharmaceuticals ... announce that it has closed a brokered private ... for approximately C$3.7 million.  Cormark Securities Inc. and ... the Brokered Offering for a syndicate of agents ... Financial Corp. (collectively the "Agents"). Concurrently with the ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... month periods ended September 30, 2014.  Biorem,s complete 2014 third quarter ... ). Financial Summary:Three-months ended September 30, , ... share data) , 2014 , 2013 ... , 5,281 , 6,715 , ...
(Date:11/18/2014)... FL (PRWEB) November 17, 2014 ... point-of-care diagnostic tests – today announces its third ... and Prevention’s (CDC) Get Smart About Antibiotics Week ... Week is a national campaign designed to highlight ... health departments, and non-profit and for-profit partners to ...
Breaking Biology Technology:International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... July 24 Abaxis, Inc.,(Nasdaq: ABAX ), a medical ... for the first,fiscal quarter ended June 30, 2008., ... 7% over last year,s comparable quarter. -- Total sales ... units or 19% over last year,s ...
... hospital physicians, pulmonary and critical care clinicians, ... about overuse of antibiotics, DURHAM, N.C., July ... conferences of the American Thoracic Society and,Society of ... care physicians, and researchers are unanimous in their ...
... 24 Glasses embedded with a telescope,promise to ... to drive and do,other activities requiring sharper distance ... of these innovative glasses,over earlier devices in an ... Biomedical Optics, mailed to subscribers in print form ...
Cached Biology Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 8U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis 2U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis 3Telescope Embedded in Spectacle Lens Promises to Make Driving Easier for Visually Impaired 2Telescope Embedded in Spectacle Lens Promises to Make Driving Easier for Visually Impaired 3
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
(Date:11/7/2014)... by Dr. Debra Auguste, associate professor, biomedical engineering, ... City College of New York, have identified a ... one of the most aggressive forms of breast ... a high mortality rate owing to aggressive proliferation ... options. However, Professor Auguste,s team, discovered the overexpression ...
(Date:11/6/2014)... deaths occur because of metastasis, yet progress in ... slow. , "It,s been particularly challenging to design ... research fellow in systems biology at Harvard Medical ... until after they,ve already metastasized." , Gujral and ... should help researchers better understand how metastasis begins. ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Migration negation 2Migration negation 3
... has been shown to improve the neurological function ... University of Traditional Chinese Medicine, China showed that ... cells positive for 5-bromodeoxyuridine, a cell proliferation-related marker, ... growth-associated protein 43, a marker of synaptic plasticity ...
... potential is the direct current potential difference between the ... Its initial amplitude is a significant indicator of the ... well as injury current, can be modulated by direct ... electrical field are hard to define. Dr. Guanghao Zhang ...
... 6, 2013 /PRNewswire-iReach/ -- IdentiSys Inc., North America,s ... card issuance, emergency response, and access control security systems, ... world,s leader in Customer and Patient Experience Management systems. ... from Qmatic to the marketplace and will be the ...
Cached Biology News:IdentiSys brings Qmatic Q-Guide Queuing Systems to the North American market 2IdentiSys brings Qmatic Q-Guide Queuing Systems to the North American market 3
Kit containing MACS equipment and reagents for immunopurification of proteins....
... LCMSsolution software offers an intuitive, ... instrument control, diverse data handling, ... requirements. Comprehensive functions include data ... data management in both standalone ...
... a modern flow cytometer, a scientist can ... labeled with fluorescent probes. However, the emission ... cell labeling are broader than the light ... filters. Thus, the fluorescence signal of a ...
... Sigmas FLAG Immunoprecipitation kit allows a ... of an active FLAG-tagged protein. The ... gel, which is a highly specific ... resin. The use of affinity resin ...
Biology Products: